Amphipathic polymer-mediated uptake of trehalose for dimethyl sulfoxide-free human cell cryopreservation

This item was submitted to Loughborough University’s Institutional Repository by the/an author.

Citation: SHARP, D.M.C. ... et al., 2013. Amphipathic polymer-mediated uptake of trehalose for dimethyl sulfoxide-free human cell cryopreservation. Cryobiology, 67 (3), pp. 305 - 311.

Additional Information:

- This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Full details of the CC BY licence are available at: http://creativecommons.org/licenses/by/3.0/

Metadata Record: https://dspace.lboro.ac.uk/2134/14244

Version: Published

Publisher: © The Authors. Published by Elsevier Inc.

Please cite the published version.
This item is distributed via Loughborough University’s Institutional Repository (https://dspace.lboro.ac.uk/) and is made available under the following Creative Commons Licence conditions.

For the full text of this licence, please go to:
http://creativecommons.org/licenses/by/3.0/
Amphipathic polymer-mediated uptake of trehalose for dimethyl sulfoxide-free human cell cryopreservation

Duncan M.C. Sharp a,*, Andrew Picken b, Timothy J. Morris b, Christopher J. Hewitt b, Karen Coopman b, Nigel K.H. Slater a

a Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museum Site, Pembroke Street, Cambridge CB2 3RA, UK
b Centre for Biological Engineering, Department of Chemical Engineering, Loughborough University, LE11 3TU, UK

A R T I C L E   I N F O
Article history:
Received 19 June 2013
Accepted 3 September 2013
Available online 14 September 2013

Keywords:
Cryopreservation
Trehalose
Biopolymer
SAOS-2
PP-50

A B S T R A C T
For stem cell therapy to become a routine reality, one of the major challenges to overcome is their storage and transportation. Currently this is achieved by cryopreserving cells utilising the cryoprotectant dimethyl sulfoxide (Me2SO). Me2SO is toxic to cells, leads to loss of cell functionality, and can produce severe side effects in patients. Potentially, cells could be frozen using the cryoprotectant trehalose if it could be delivered into the cells at a sufficient concentration. The novel amphipathic membrane permeabilising agent PP-50 has previously been shown to enhance trehalose uptake by erythrocytes, resulting in increased cryosurvival. Here, this work was extended to the nucleated human cell line SAOS-2. Using the optimum PP-50 concentration and media osmolarity, cell viability post-thaw was 60 ± 2%. In addition, the number of metabolically active cells 24 h post-thaw, normalised to that before freezing, was found to be between 103 ± 4% and 91 ± 5%. This was found to be comparable to cells frozen using Me2SO. Although reduced (by 22 ± 2%, p = 0.09), the doubling time was found not to be statistically different to the non-frozen control. This was in contrast to cells frozen using Me2SO, where the doubling time was significantly reduced (by 41 ± 4%, p = 0.004). PP-50 mediated trehalose delivery into cells could represent an alternative cryopreservation protocol, suitable for research and therapeutic applications.

© 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Introduction

In recent years, the developed world has seen an increase in demand for tissue replacement. While the number of donor organs and organs has remained relatively static, the number of patients on the transplant waiting list for kidney, pancreas, heart, lung, and liver has increased [31]. It is hoped that regenerative medicine, including stem cell-based therapies, could meet this need, as well as providing novel treatments for currently incurable conditions [39].

For stem cell-based therapies to be used routinely in a clinical setting, these cells must be stored and transported. Currently this need is met through cryopreservation, often using the cryoprotectant dimethyl sulfoxide (Me2SO). However, the viability of both adult and embryonic stem cells has been found to be significantly decreased by cryopreservation using Me2SO [20,42]. Perhaps more seriously, the functionality of cells can be adversely affected. For example, Katkov et al. [20] found that only 5–10% of human embryonic stem cells (hESCs) expressed the transcription factor Oct-4, a marker of pluripotency, following Me2SO cryopreservation. This property of facilitating the loss of hESCs pluripotency has been utilised in hESC differentiation protocols [14]. Cryopreservation using Me2SO may also have contributed to the failure of a phase III clinical trial using human mesenchymal stromal cells, due to loss of cell viability and functionality [17]. Indeed, it has been found that the genome-wide DNA methylation profiles of cells can be altered by Me2SO [40].

In addition, patients may experience severe side effects from Me2SO toxicity after cells preserved in this cryoprotectant are transplanted. These include cardiac arrest, severe respiratory arrest, severe neurotoxicity and epileptic seizures [12]. These side effects are thought to occur in one in 70 patients following autologous bone marrow transplantation [44]. Although this issue could be overcome by washing cells prior to implantation, this increases the complexity of the cell delivery method and could result in significant cell losses. Therefore there is a demand for Me2SO-free cryopreservation techniques, utilising non-toxic cryoprotectants, which maintain cell viability and functionality.
The non-permeating cryoprotectant trehalose may provide an alternative, however to provide maximum protection to the cells, the trehalose should be present on both sides of the cell membrane [15]. Recently, the amphiphatic membrane permeabilising polymer PP-50 has been used to load human erythrocytes with trehalose, which led to a significant enhancement in cryosurvival [27]. PP-50, which can be removed from cell membranes by a small change in pH [26], is thought to be non-cytotoxic [11,22]. This is in stark contrast to previous studies using pore-forming bacterial toxins [16,15], where serious health concerns have been raised regarding the use of these proteins [32,41].

A number of alternative methods for the delivery of trehalose into cells have previously been employed [4,5], These include the use of the ATP receptor channel P2X7 [19] or endocytosis [18,30,33]. Stimulation of the P2X7 channel may lead to apoptosis, necrosis [2] or even neoplasia [3]. The latter two methods also have the disadvantage of requiring incubation times of 24 h or more. This is in contrast to the proposed method of PP-50 mediated trehalose delivery [27].

In the current study, the techniques for the cryopreservation of cells using trehalose and PP-50 developed by Lynch et al. [27] were extended to successfully preserve nucleated human cells. The Human osteosarcoma derived cell line SAOS-2 [16,35] was used as a model for nucleated, adherent human cells.

Methods and materials

Materials

Unless otherwise stated, all reagents were purchased from Sigma–Aldrich (UK). Materials for the PP-50 polymer synthesis were sourced as previously described [25]. Foetal bovine serum (FBS), l-glutamine, and penicillin/streptomycin were purchased from Invitrogen (UK). Dulbecco's Phosphate-Buffered Saline (DPBS, 10× DPBS and trypsin–EDTA were purchased from Life Technologies™ (UK). The CellTiter 96® AQueous One Solution Proliferation Assay (MTS) was purchased from Promega (UK). The SAOS-2 cells were purchased from the European Collection of Cell Cultures. The Annexin V-FITC Apoptosis Detection Kit was purchased from BD Biosciences (UK).

PP-50 synthesis and characterisation

The synthesis and characterisation of the PP-50 polymer were as previously described by Lynch et al. [25].

Cell culture

SAOS-2 cells were grown in tissue culture flasks containing “growth media”: Dulbecco’s Modified Eagle’s Medium – high glucose (DMEM), supplemented with 10% (v/v) FBS, l-glutamine (2 mM), penicillin/streptomycin (100 μg/ml) at approximately 70% confluency, the cells were subcultured with trypsin (0.05% w/v) and EDTA (0.02% w/v), and were subsequently split at a ratio of 1:6. The cells were maintained in a humidified incubator at 37°C with 5% CO2, a positive control for PI staining was prepared by fixation with paraformaldehyde solution (4% w/v, in DPBS) for 10 min, followed by washing (>3) with DPBS.

For the remaining dishes, the cells were washed twice with DPBS. Afterwards, the cells were incubated for 4 h in serum-free media supplemented with 0.2 M trehalose, 2 mM calcein, and with or without PP-50 (200 μg/ml), at pH 7.05. The cells were washed twice with DPBS, and incubated with growth media containing Hoechst 33342 (2 μg/ml) and PI (2 μg/ml) for 15 min. Following three washes with DPBS, the cells were imaged using a TCS SP5 inverted laser scanning confocal microscope (Leica, Germany).

PP-50 toxicity

SAOS-2 cells were seeded into 96-well tissue culture plastic plates (Corning, UK) at 5000 cells/well. After 24 h, the cells were washed twice with DPBS at either pH 7.4 or pH 7.05. The cells were incubated (37°C with 5% CO2) in serum-free growth media containing different PP-50 concentrations (0–1000 μM) at pH 7.4 or pH 7.05, for 2 or 24 h. The cells incubated for 2 h were subsequently washed with DPBS and incubated for 22 h in growth media. An MTS assay was performed at the 24 h mark according to the manufacturer’s instructions.

Cryopreservation and reconstitution

SAOS-2 cells were seeded into 6-well tissue culture plastic plates (Corning, UK) at 105 cells/well. After 24 h, the cells were washed twice with DPBS (pH 7.4), then DPBS (pH 7.05), and were then incubated (37°C with 5% CO2) in “incubation media”: serum-free media with 0.2 M trehalose, with or without PP-50 at different concentrations, and water (18.2 MΩ.cm, Milli-Q® filtered, Millipore, USA), at pH 7.05. Following incubation, the osmolarity of all solutions was adjusted to that of the incubation media using 10× DPBS (PAA, UK) and/or water unless otherwise stated.

After 2 h of incubation (37°C with 5% CO2), the cells were washed twice with DPBS, and trypsin/EDTA was added at 200 μl/well. After 15 min of incubation (37°C with 5% CO2), 500 μl/well growth media was added and the cells were centrifuged at 350 g for 5 min and resuspended in 150 μl of 0.2 M trehalose in FBS. Controls using un-incubated cells were also prepared and resuspended in FBS (90%) and Me2SO (10%). All samples were transferred into cryovials (Greiner, UK), and transferred into an isopropanol freezing container (Nalgene, USA), then passively cooled in a –80°C freezer overnight, before storage in vapour-phase liquid nitrogen for at least 48 h.

The cells were subsequently thawed by immersing the cryovials in a 37°C water-bath, after which 850 μl/cryovial of cryogrowth media were slowly added. After centrifugation, the cells were resuspended in growth media, and added to the wells of 96-well plates (100 μl/well). Non-frozen SAOS-2 cells were seeded into the plates at 5000 cells/well. After 4 h of incubation (37°C with 5% CO2), the media was changed to growth media of normal osmolarity. MTS assays were subsequently performed at 24, 48 and 72 h, according to the manufacturer’s instructions.

\[
\begin{align*}
{t_d} &= (t_2 - t_1) \frac{\ln 2}{M \cdot W(1)} \\
N(0) &= \frac{N(24)}{2^{t_d}}
\end{align*}
\]

The number of metabolically active cells was found using a standard curve. The doubling times, \(t_d\), were calculated using Eq. (1), where \(t_1\) and \(t_2\) represent the time at time-points 1 and 2, respectively, and \(N(t_1)\) and \(N(t_2)\) represent the number of cells at
Viability and apoptosis assay

SAOS-2 cells were seeded into 25 cm² tissue culture flasks (Corning, UK) at 5 × 10⁵ cells/flask. After 24 h, the cells were frozen as described above, scaling volumes appropriately for the growth area. The freezing protocols used were; 0.2 M trehalose (additional 133 mOsm/l) with or without 25 µg/ml PP-50, and the Me₂SO control. Following thawing of the cells, using a 37 °C water-bath, an Annexin V/PI flow cytometry assay was performed. The manufacturer’s instructions were followed, with the modification that for the cells frozen with trehalose, the osmolarity of all reagents was adjusted with an additional 133 mOsm/l of sodium chloride. The samples were examined using a FACScan flow cytometer (Becton Dickinson, USA).

Statistical analysis

All statistical data analysis was performed using the statistical software package SPSS 14.0 for Windows. The data for the numbers of metabolically active cells at 24 h post-thaw, the doubling times and the flow cytometry data were analysed by one-way ANOVA followed by Tukey HSD. Values of p < 0.05 were considered to be statistically significant [45].

All data quoted represent the mean of three repeats ± the standard error of the mean (SEM), unless otherwise stated.

Results

Calcein and propidium iodide fluorescence assay

Cells incubated in the presence of trehalose and calcein stained weakly with calcein (Fig. 1). The calcein staining of the cells in the presence of the cell permeabilising polymer PP-50 was found to be stronger. For the non-fixed cells, no PI positive cells were observed.

PP-50 toxicity

In the experimental range tested, it was found that pH had no significant effect on metabolic activity (Fig. 2). PP-50 at 1000 µg/ml significantly decreased metabolic activity for all incubation conditions tested. For PP-50 concentrations ≤50 µg/ml, there was a small but statistically significant increase in metabolic activity when the cells were incubated for 24 h in the presence of the polymer.

Cryopreservation and reconstitution

The number of metabolically active cells present 24 h post-thaw, was determined from the MTS assay. These data were normalised by the number of cells present in the pre-freeze samples, taking dilution into account (Fig. 3). The post-thaw recovery of the cells incubated with trehalose in the absence of PP-50 was found to be 68 ± 5%. Of the concentrations tested, only 25 µg/ml of PP-50 in the pre-freeze incubation media was found to significantly enhance the cell recovery (103 ± 4%, p = 0.034). Although the cell recovery was greater in the Me₂SO control group (130 ± 14%), this was found not to be statistically significant. The fact that this group had a higher 24 h post-thaw recovery than 100%, may be explained by proliferation of the cells during the first 24 h. Making the assumption that the different cell doubling times, specific to each treatment group, remained the same throughout the experiment, the number of viable cells capable of proliferating immediately post-thaw was calculated to be 64 ± 5% and 70 ± 11% for the PP-50/trehalose and Me₂SO treatments, respectively. Using the same calculation, the number of proliferative cells for the non-frozen control was 116 ± 6%.

For the freezing protocol involving PP-50 and trehalose, the osmolarity of the incubation and freezing media was optimised (Fig. 4). The optimum additional osmolarity was found to be 133 mOsm/l, with a 24 h cell recovery of 91 ± 5%.

The proliferation of the SAOS-2 cells post-thaw was examined (Fig. 5). It was found that when the concentration of PP-50 in the incubation media was >50 µg/ml, the cells did not proliferate at the normal rate compared to cells kept in continuous culture (non-frozen control). However, when the concentration was ≤25 µg/ml the growth curves were similar to the non-frozen control. This was also reflected in the doubling times for the cells. Although reduced (by 22 ± 2%, p = 0.09) these two groups were not significantly different from the non-frozen control (Fig. 6).

In contrast, the cells frozen using Me₂SO were found to have an abnormally high rate of growth. This was also reflected in the doubling time for the cells (Fig. 6), which for this group was significantly different from the non-frozen control during the test period (reduced by 41 ± 4%, p = 0.004).

Viability and apoptosis assay

To determine the cell cryosurvival, the post-thaw viability of the cells was determined by flow cytometry using Annexin V-FITC and PI staining (Fig. 7). The percentage of viable cells was significantly higher for the cells frozen using Me₂SO (80 ± 3%) than for either treatment using trehalose with or without PP-50 (60 ± 2%, and 44 ± 3%, respectively). The addition of PP-50 at 25 µg/ml during the incubation step, significantly enhanced viability (by a factor of 37 ± 7%, p = 0.002). For all the treatment groups tested, the majority of the non-viable cells were found to be necrotic rather than apoptotic.
Discussion

Perhaps the two most important criteria with which different methods of cell cryopreservation should be judged are; cryosurvival and retention of normal cell processes. The latter is thought to be particularly important for both research and therapeutic applications. Here, a Me$_2$SO-free cryopreservation protocol, using trehalose delivery utilising PP-50, was developed and assessed. The cell line SAOS-2 was used as a model for nucleated, adherent human cells.

Calcein and propidium iodide fluorescence assay and PP-50 toxicity

Calcein, like trehalose, is thought to be impermeable to the cell membrane. Calcein has therefore been used in previous studies to assess the extent of delivery of hydrophilic species into cells [10,11]. The degree of calcein uptake in the presence of the PP-50 was less than that previously reported for the related polymer PP-75 [10,11]. In part, this may be explained by the presence of trehalose in the incubation media in the studies described above. This
increase in osmotic pressure caused by the trehalose supplementa-
tion of the media, may have decreased the rate of endocytosis for
the cells [34]. Endocytosis has previously been found to play an
important role in the delivery of hydrophilic species into cells
using the related polymer PP-75 [21]. However since the delivery
of trehalose into human erythrocytes which do not perform endo-
cytosis, has previously been demonstrated [27], delivery through
the cell membrane may also be important. It was concluded that
PP-50 was capable of delivering hydrophilic species, such as treha-
lose, into cells. It should be noted that the PP-50 appeared to in-
crease the rate of uptake of hydrophilic species by endocytosis
compared to the control (Fig. 1). In addition to the release of treha-
louse into the cytoplasm, trehalose in endosomes may also have
contributed to the efficacy of the PP-50/trehalose cryopreservation
protocol [33].

Propidium iodide which is incapable of staining cells with intact
 cell membranes, has been widely used to assess the viability of
cells [11, 28, 38]. In the experiments described above, PI staining
was used to determine the viability of the cells, and whether the
membrane permeabilising effect of the PP-50 could be reversed
by washing with pH 7.4 DPBS. Previous studies have found that
the hydrophobicity of PP-50 is strongly affected by pH. The poly-
mer's ability to bind to the hydrophobic core of cell membranes
is thought to be significantly higher at pH 7.05 than at pH 7.4
[25]. Indeed, this pH change has been found to be sufficient to re-
move PP-50 bound to cell membranes [26]. For the group previ-
ously permeabilised by PP-50, no PI positive cells were observed
(Fig. 1). These data suggest that the permeabilising effect of PP-
50 is reversible and is in agreement with previous studies by Lynch
et al. [26].

The metabolic activity of SAOS-2 cells was assessed after either
a 2 or 24 h challenge with PP-50. This was conducted both at pH
7.05, at which the polymer is thought to have a permeabilising ef-
ficacy on cell membranes, and pH 7.4, at which the polymer is
thought not to associate with cell membranes. No toxic effect
was observed for PP-50 concentrations < 200 μg/ml. No significant
decrease in metabolic activity was observed for these polymer con-
centrations at both permeabilising and non-permeabilising pHs
(Fig. 2). In addition, no PI positive cells were observed when incu-
bated with PP-50 at 200 μg/ml (Fig. 1). This was in agreement with
previous studies [11, 22].

Interestingly, there was a small but statistically significant in-
crease in metabolic activity when the cells were incubated for
24 h in the presence of the polymer. This may be due to the cells under “serum starving” conditions, metabolising the PP-50. Alternatively, the cells may have been more metabolically active in response to loss of elements from the cytoplasm, caused by membrane permeabilisation by the PP-50.

**Cryopreservation and reconstitution**

Extracellular concentrations of 0.2 M trehalose have previously been used in the cryopreservation of nucleated mammalian cells [6,9,15,29]. Since the osmotic coefficient of trehalose in aqueous solutions is 1.01 [43], 0.2 M trehalose yields an increase in osmolarity of approximately 200 mOsm/l. Increasing the normal osmolarity of media by more than 200 mOsm/l, can lead to apoptosis of the majority of cells [13]. Lynch et al. [27] had found that altering the PP-50 concentration in the presence of trehalose in the incubation media, determined the resulting intracellular trehalose loading. The concentration of PP-50 in the incubation media was therefore altered to determine the polymer concentration leading to an optimal delivery of trehalose into the cells. Of the concentrations tested, the optimum PP-50 concentration was found to be 25 µg/ml. This was both in terms of the cell recovery at 24 h post-thaw, and minimising differences in doubling time from the non-frozen control.

Freezing media consisting of 10% Me₂SO and 90% FBS was chosen as the control cryopreservation media. Media such as this has been widely used in previous studies [23,36,37]. The 24 h cell recovery for the optimum PP-50 concentration (103 ± 4%) was found to be less than that for the Me₂SO control (130 ± 14%), although this difference was not statistically significant. In part, this may be explained by proliferation of the SAOS-2 cells during the first 24 h post-thaw. Assuming the cell doubling times remained constant throughout the experiment, the number of viable cells capable of proliferating immediately post-thaw for the PP-50/ trehalose and Me₂SO protocols was estimated to be comparable (64 ± 5% and 70 ± 11%, respectively). This estimated cryosurvival was similar to that achieved for mesenchymal stem cells by Wang et al. [42]. Hence the cryosurvival of proliferative cells achieved using the PP-50/trehalose treatment may have been comparable to the Me₂SO control. It should be noted that MTS assays were not performed on the cells immediately post-thaw, as the presence of early apoptotic cells can yield misleading results [24], as could the presence of cells incapable of substrate attachment.

The cryosurvival immediately post-thaw was tested further for these protocols, using a flow cytometry based Annexin V/PI assay. The proportion of viable cells for the PP-50/trehalose and Me₂SO protocols were found to be comparable to those calculated above (80 ± 3% and 60 ± 2%, respectively). This could indicate that there is not a significant sub-population of cells for either protocol that appears viable, but is non-proliferative during subsequent culture. As discussed previously, Me₂SO is currently the cryoprotectant of choice for most cell culture and therapeutic applications. Although there is scope for improving the number of cells that survive the freezing process, the two most concerning problems associated with the use of Me₂SO are loss of cell functionality, and toxicity to patients. Therefore, of the outcome measures tested, the comparison of the cell doubling times to the non-frozen control was thought to be the more important. It was found that the rate of proliferation was abnormally high for the cells cryopreserved using Me₂SO compared to non-frozen SAOS-2 cells (Fig. 5). Indeed the cell doubling times were found to be significantly different from the non-frozen control by 41 ± 4%. In contrast, the doubling time for the cells cryopreserved using the optimum PP-50/trehalose protocol did not significantly affect the doubling time (Fig. 6).

These data suggest that the normal processes of the cells were affected less when cryopreserved using PP-50/trehalose than Me₂SO, while maintaining high cell recovery. In addition, cells cryopreserved using this technique, would not contain traces of Me₂SO, and therefore have the potential to reduce the side effects experienced by patients receiving transplants of cryopreserved cells. Subject to future development and testing, PP-50 mediated delivery of trehalose into cells could represent an alternative to conventional cell cryopreservation protocols for both therapeutic and research applications.

**Conclusions**

In this study, the feasibility of a cellular cryopreservation protocol, utilising PP-50 mediated delivery of trehalose into cells, was assessed using SAOS-2 cells. The concentrations of PP-50, as well as the osmotic pressure of the incubation and freezing solutions, were optimised. The optimum PP-50/trehalose cryopreservation protocol yielded comparable cell recovery at 24 h post-thaw to cells cryopreserved using Me₂SO. Cryopreservation using the PP- 50/trehalose protocol, did not significantly affect the cell doubling time, in contrast to Me₂SO cryopreservation. After future development and testing, delivery of trehalose utilising PP-50, could form the basis of a cryopreservation protocol superior and safer to those based on Me₂SO, for research and therapeutic applications.

**References**


